RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Giant Cell Tumour of Bone: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Role of neoadjuvant denosumab in pathological fracture associated giant cell tumor of bone: a retrospective case series
Badaruddin Sahito et al., BMC Musculoskeletal Disorders (16 October 2026)
https://doi.org/10.1186/s12891-026-10595-5
- 2.
Modern Radiotherapy for Axial Giant Cell Tumor of Bone: Impact of Gross Disease at Treatment Initiation.
Baek Jong Yun et al., American journal of clinical oncology (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42893582/
- 3.
Stability with Preserved Intercarpal Joint Mobility After Distal Radius Resection for Giant Cell Tumour of Bone: Early Results of a Refined Surgical Technique
Navaneeth Kamath et al., Indian Journal of Orthopaedics (7 October 2026)
https://doi.org/10.1007/s43465-026-01998-6
- 4.
Receptor tyrosine kinase inhibitors trametinib and axitinib effectively target the neoplastic component of giant cell tumor of bone in vitro
Veronika Knechtova et al., bioRxiv (Cold Spring Harbor Laboratory) (6 October 2026)
https://doi.org/10.64898/2026.10.06.756991
- 5.
Homoeopathic perspectives in giant cell tumour of bone
Amiben H Panchal et al., International Journal of Homoeopathic Sciences (1 October 2026)
https://doi.org/10.33545/26164485.2026.v10.i10c.3322
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
NCT03301857 · Completed · Phase 4 · Amgen
https://clinicaltrials.gov/study/NCT03301857
- 2.
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
NCT00680992 · Completed · Phase 2 · Amgen
Ages 12 and over
https://clinicaltrials.gov/study/NCT00680992
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Giant Cell Tumour of Bone
Giant Cell Tumour of Bone is a rare bone tumour that most often affects young adults. It is usually non-cancerous but can grow aggressively. Surgery is the main treatment, but the tumour sometimes comes back. Researchers are actively studying new treatment options.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Denosumab (DMAb) is widely used as a neoadjuvant therapy to downstage giant cell tumor of bone (GCTB). However, increasing evidence demonstrates that neoadjuvant DMAb may increase the local recurrence (LR) risk following curettage of GCTB. It remains unclear about the potential mechanisms for neoadjuvant DMAb-associated LR of GCTB. Here, we perform single-cell RNA sequencing on untreated primary GCTB, neoadjuvant DMAb-treated primary GCTB, and relapsed GCTB following discontinuation of DMAb after curettage. A total of 33,440 cells are obtained. Osteoclast-like giant cells nearly disappear in primary GCTB after neoadjuvant DMAb treatment, but rebound following DMAb discontinuation in recurrent GCTB. Neoadjuvant DMAb therapy induces the transformation of TNFSF11 (RANKL)-positive neoplastic cells into SPP1 (osteopontin)-positive and CA2-positive neoplastic cells. Neoadjuvant DMAb therapy induces a durable intratumoral immunosuppressive environment, characterized by an increased frequency of regulatory T cells and decreased levels of cytotoxic CD8+ T cells and natural killer T (NKT) cells. In addition, DMAb-induced differentiation of monocytes to Trem2+ macrophages provides a favorable microenvironment that facilitates tumor relapse. CSF1R inhibitor can inhibit the tumor growth of recurrent GCTB. Targeting CSF1R and alleviating T cell exhaustion may provide therapeutic insights for the management of relapsed GCTB following DMAb discontinuation.
Common Questions
What is Giant Cell Tumour of Bone?
Giant Cell Tumour of Bone is a rare bone tumour that most often affects young adults. It is usually non-cancerous but can grow aggressively. Surgery is the main treatment, but the tumour sometimes comes back. Researchers are actively studying new treatment options.
How many clinical trials are available for Giant Cell Tumour of Bone?
RareWays currently indexes 14 clinical trials for Giant Cell Tumour of Bone, of which 4 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Giant Cell Tumour of Bone come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Giant Cell Tumour of Bone.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.